Overview
To investigate clinical and survival outcomes following transcatheter tricuspid valve repair or replacement.
Description
Background and Rationale:
Tricuspid regurgitation (TR) is a major health and economic burden due to high rates of heart failure hospitalizations, morbidity and mortality. Surcial treatment of TR is associated with high procedural and in-hospital mortality. Due to prohibitive surgical risk, a significant proportion of patients historically remained untreted beyond medical therapy. Transcatheter tricuspid valve (TV) repair and replacement techniques (TTVT) now offer a new treatment perspective for these patients. The EuroTR registry aims at optimizing patient selection prior to TTVT and thus treatment quality by collecting respective data in a real-world setting.
- Objectives
To investigate clinical and survival outcome following transcatheter tricuspid valve repair or replacement.
Eligibility
Inclusion Criteria:
- Patients treated with one of the following transcatheter devices for TV repair or replacement: PASCAL, TriClip, TricValve, Evoque, LuX-Valve
- Age ≥ 18 years